Xilio Development Stock Today
| XLO Stock | USD 0.66 0 0.30% |
PerformanceWeak
| Odds Of DistressVery High
|
Xilio Development is selling at 0.662 as of the 16th of June 2025; that is 0.30 percent increase since the beginning of the trading day. The stock's open price was 0.66. Xilio Development has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 21st of June 2024 and ending today, the 16th of June 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of October 2021 | Category Healthcare | Classification Health Care |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. Xilio Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 51.78 M outstanding shares of which 791.48 K shares are at this time shorted by investors with about 0.3 days to cover. More on Xilio Development
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Xilio Stock Highlights
| CEO President | PharmD BCPS | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsXilio Development can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Xilio Development's financial leverage. It provides some insight into what part of Xilio Development's total assets is financed by creditors.
| |||||
Xilio Development (XLO) is traded on NASDAQ Exchange in USA. It is located in 828 Winter Street, Waltham, MA, United States, 02451 and employs 64 people. Xilio Development is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 34.3 M. Xilio Development runs under Biotechnology sector within Health Care industry. The entity has 51.78 M outstanding shares of which 791.48 K shares are at this time shorted by investors with about 0.3 days to cover.
Xilio Development has about 159.41 M in cash with (18.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Xilio Development Probability Of Bankruptcy
Ownership AllocationXilio Development retains a total of 51.78 Million outstanding shares. Xilio Development owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Xilio Ownership Details
Xilio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2025-03-31 | 177.7 K | |
| Honkamp Krueger Financial Services Inc | 2025-03-31 | 150.4 K | |
| Two Sigma Investments Llc | 2025-03-31 | 84.1 K | |
| Blackrock Inc | 2025-03-31 | 74.7 K | |
| Bridgeway Capital Management, Llc | 2025-03-31 | 71.1 K | |
| Northern Trust Corp | 2025-03-31 | 66.6 K | |
| Millennium Management Llc | 2025-03-31 | 51.1 K | |
| Aptus Capital Advisors, Llc | 2025-03-31 | 46 K | |
| Sevenbridge Financial Group, Llc | 2025-03-31 | 46 K | |
| Bain Capital Life Sciences Investors, Llc | 2025-03-31 | 4.6 M | |
| Merck & Co Inc | 2025-03-31 | 1.5 M |
Xilio Development Historical Income Statement
Xilio Stock Against Markets
Xilio Development Corporate Management
| Kevin Brennan | Senior Accounting | Profile | |
| Martin MD | Pres RD | Profile | |
| Scott Coleman | Chief Officer | Profile | |
| Uli Bialucha | Chief Officer | Profile | |
| Bill Avery | VP Devel | Profile | |
| Caroline Hensley | Chief Officer | Profile |
Already Invested in Xilio Development?
The danger of trading Xilio Development is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xilio Development is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xilio Development. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xilio Development is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Xilio Development offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xilio Development's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xilio Development Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xilio Development Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xilio Development. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xilio Development. If investors know Xilio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xilio Development listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xilio Development's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.